AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32294346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study 33919630 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean dietary pattern (MDP) adherence
Number of subjects: 175
Study 33919630 — intervention group
Group type: COMPARATOR
Intervention: Breakfast quality
Number of subjects: 175
Study 33919630 — intervention group
Group type: COMPARATOR
Intervention: Physical activity adjustment
Number of subjects: 175
Study 32076003 — intervention group
Group type: EXPERIMENTAL
Intervention: Social network intervention (random assignment into small groups at an introduction event two months prior to university)
Number of subjects: 0
Study 32024793 — intervention group
Group type: EXPERIMENTAL
Intervention: PARTNER model of service delivery
Number of subjects: 0
Study 32024793 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 35349757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir treatment
Number of subjects: 217
Study 35349757 — intervention group
Group type: COMPARATOR
Intervention: No ganciclovir treatment (Control)
Number of subjects: 217
Study 35349757 — intervention group
Group type: COMPARATOR
Intervention: Nonsurvivors (Control)
Number of subjects: 217
Study 33340245 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg
Number of subjects: 86
Study 33340245 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin 300 mg
Number of subjects: 86
Study 32289471 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes coping skills training (DCST) intervention plus diabetes education
Number of subjects: 0
Study 32289471 — intervention group
Group type: COMPARATOR
Intervention: Diabetes education alone
Number of subjects: 0
Study 35739147 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal aflibercept (IVA) monotherapy
Number of subjects: 51
Study 35739147 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVA) + subthreshold laser (SL) combination therapy
Number of subjects: 51
Study 32616406 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodynamics (UDS)
Number of subjects: 820
Study 32616406 — intervention group
Group type: COMPARATOR
Intervention: Routine Care (RC)
Number of subjects: 820
Study 32616406 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 820
Study 32686217 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulphate irritation
Number of subjects: 0
Study 32686217 — intervention group
Group type: EXPERIMENTAL
Intervention: Tape stripping
Number of subjects: 0
Study 32686217 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet radiation
Number of subjects: 0
Study 32686217 — intervention group
Group type: EXPERIMENTAL
Intervention: Tested preparation
Number of subjects: 0
Study 32686217 — intervention group
Group type: COMPARATOR
Intervention: Control, undamaged site
Number of subjects: 0
Study 33081817 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with macrolide azithromycin and hydroxychloroquine
Number of subjects: 0
Study 33081817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35381930 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroendoscopic surgery (NES)
Number of subjects: 83
Study 35381930 — intervention group
Group type: COMPARATOR
Intervention: Extraventricular drainage (EVD)
Number of subjects: 83
Study 34322703 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax plus low-dose cytarabine
Number of subjects: 27
Study 34322703 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus low-dose cytarabine
Number of subjects: 27
Study 32614227 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociometric Badge (SB) condition (n = 75 dyads)
Number of subjects: 306
Study 32614227 — intervention group
Group type: COMPARATOR
Intervention: Standard recording device condition (n = 78 dyads)
Number of subjects: 306
Study 35865301 — intervention group
Group type: EXPERIMENTAL
Intervention: MA VR scene + TBS
Number of subjects: 45
Study 35865301 — intervention group
Group type: COMPARATOR
Intervention: MA VR scene + sham TBS
Number of subjects: 45
Study 35865301 — intervention group
Group type: EXPERIMENTAL
Intervention: neutral VR scene + TBS
Number of subjects: 45
Study 32981091 — intervention group
Group type: EXPERIMENTAL
Intervention: Helping Mothers Survive Bleeding after Birth training
Number of subjects: 58000
Study 33066061 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates method with therapeutic exercise
Number of subjects: 25
Study 33066061 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic exercise
Number of subjects: 25
Study 36200820 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 80
Study 36200820 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Compression Pumps
Number of subjects: 80
Study 34794061 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid Craving Visual Analog Scale (OC-VAS)
Number of subjects: 487
Study 34978954 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal stabilization exercises (SSE)
Number of subjects: 10
Study 34978954 — intervention group
Group type: COMPARATOR
Intervention: Home exercise program (control)
Number of subjects: 10
Study 33798287 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol treatment
Number of subjects: 184
Study 33798287 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 184
Study 33268629 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic wave vibration (SWV) for 10 minutes per day, 5 days a week for 8 weeks
Number of subjects: 24
Study 33268629 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic wave vibration (SWV)
Number of subjects: 24
Study 33268629 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 32496892 — intervention group
Group type: EXPERIMENTAL
Intervention: Benefit-finding intervention
Number of subjects: 68
Study 32496892 — intervention group
Group type: COMPARATOR
Intervention: Routine health education (Control)
Number of subjects: 68
Study 32266412 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention tests including the Digit Span Test (DST)
Number of subjects: 89
Study 32266412 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention tests including the Symbol Digit Modalities Test (SDMT)
Number of subjects: 89
Study 32266412 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention tests including the Paced Auditory Serial Addition Test (PASAT)
Number of subjects: 89
Study 32266412 — intervention group
Group type: COMPARATOR
Intervention: Digit Cancellation Test (D-CAT1 and D-CAT2)
Number of subjects: 89
Study 35255426 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanidin‐ and delphinidin‐rich extract (CDRE) providing 320.4 mg of anthocyanins (90% cyanidin and delphinidin)
Number of subjects: 25
Study 35255426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 34663236 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced mammography (CEM)
Number of subjects: 440
Study 34663236 — intervention group
Group type: COMPARATOR
Intervention: No further imaging (Control)
Number of subjects: 440
Study 34663236 — intervention group
Group type: EXPERIMENTAL
Intervention: CEM
Number of subjects: 440
Study 36183049 — intervention group
Group type: EXPERIMENTAL
Intervention: IP-SSCV
Number of subjects: 250
Study 36183049 — intervention group
Group type: COMPARATOR
Intervention: OOP-IJV
Number of subjects: 250
Study 33738617 — intervention group
Group type: EXPERIMENTAL
Intervention: Minodronate
Number of subjects: 3247
Study 33738617 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene
Number of subjects: 3247
Study 32416821 — intervention group
Group type: COMPARATOR
Intervention: 3,000 IU/kg vitamin D3 (control)
Number of subjects: 42
Study 32416821 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,000 IU/kg 25-hydroxyvitamin D3 (T1)
Number of subjects: 42
Study 32416821 — intervention group
Group type: EXPERIMENTAL
Intervention: 9,000 IU/kg 25-hydroxyvitamin D3 (T2)
Number of subjects: 42
Study 32416821 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,000 IU/kg vitamin D3 (T3)
Number of subjects: 42
Study 32416821 — intervention group
Group type: EXPERIMENTAL
Intervention: 9,000 IU/kg vitamin D3 (T4)
Number of subjects: 42
Study 32416821 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,000 IU/kg vitamin D2 (T5)
Number of subjects: 42
Study 32416821 — intervention group
Group type: EXPERIMENTAL
Intervention: 9,000 IU/kg vitamin D2 (T6)
Number of subjects: 42
Study 36322173 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive total hysterectomy and sacrocolpopexy with lightweight mesh
Number of subjects: 106
Study 33958495 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibroacoustic therapy using the VITAFON-2 apparatus
Number of subjects: 60
Study 33958495 — intervention group
Group type: COMPARATOR
Intervention: Placebo apparatus
Number of subjects: 60
Study 33154056 — intervention group
Group type: EXPERIMENTAL
Intervention: Human papillomavirus-based screening (either GP-based or self-sampling)
Number of subjects: 10000
Study 33154056 — intervention group
Group type: COMPARATOR
Intervention: Standard care (cervical cytology sample at GP or gynaecologist)
Number of subjects: 10000
Study 33154056 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling
Number of subjects: 10000
Study 35737102 — intervention group
Group type: EXPERIMENTAL
Intervention: Group iSLN: bilateral perineural injection with 4 mg dexamethasone around the internal branch of superior laryngeal nerve
Number of subjects: 161
Study 35737102 — intervention group
Group type: COMPARATOR
Intervention: Group Spray: 4 mg dexamethasone sprayed on the vocal cord
Number of subjects: 161
Study 33258032 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent treatment
Number of subjects: 43
Study 33258032 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 43
Study 33036471 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-virgin olive oil (EVO)
Number of subjects: 0
Study 33036471 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil
Number of subjects: 0
Study 33036471 — intervention group
Group type: COMPARATOR
Intervention: Animal fat
Number of subjects: 0
Study 35074322 — intervention group
Group type: EXPERIMENTAL
Intervention: PERI‐OP intervention
Number of subjects: 137
Study 35074322 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 137
Study 35219356 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment with fluvoxamine
Number of subjects: 0
Study 33261700 — intervention group
Group type: EXPERIMENTAL
Intervention: tCBT + TAU
Number of subjects: 231
Study 33261700 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 231
Study 34896916 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive educational app about VTE and anticoagulation
Number of subjects: 56
Study 34896916 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 56
Study 34467742 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 43
Study 32962981 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/severe DKA
Number of subjects: 758
Study 32962981 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/severe DKA in newly diagnosed patients
Number of subjects: 758
Study 32962981 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated DKA exposure in previously diagnosed patients
Number of subjects: 758
Study 32962981 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HbA1c in previously diagnosed patients
Number of subjects: 758
Study 35440521 — intervention group
Group type: EXPERIMENTAL
Intervention: ACB with magnesium and bupivacaine (n=56)
Number of subjects: 119
Study 35440521 — intervention group
Group type: COMPARATOR
Intervention: ACB with bupivacaine only (n=63)
Number of subjects: 119
Study 35960163 — intervention group
Group type: EXPERIMENTAL
Intervention: High cardiorespiratory fitness
Number of subjects: 185
Study 35960163 — intervention group
Group type: EXPERIMENTAL
Intervention: High or moderate cardiorespiratory fitness
Number of subjects: 185
Study 35960163 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity
Number of subjects: 185
Study 35485333 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine plus darunavir/cobicistat (25 mg rilpivirine plus 800/150 mg darunavir/cobicistat once daily)
Number of subjects: 160
Study 35485333 — intervention group
Group type: COMPARATOR
Intervention: Standard three-drug therapy (late switch group)
Number of subjects: 160
Study 35485333 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine plus darunavir/cobicistat
Number of subjects: 160
Study 35764016 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model for remission probability of LN
Number of subjects: 301
Study 33691730 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic (furosemide)
Number of subjects: 166
Study 33691730 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 166
Study 32178705 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (24-week program, 90 min once a week, at least 2 at-home sessions of 15 min each)
Number of subjects: 26
Study 32178705 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 26
Study 36459409 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (exercise, nutrition, and psychosocial programs) once a week for 8 weeks
Number of subjects: 69
Study 36459409 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 69
Study 36459409 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 69
Study 33773391 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimicoxib
Number of subjects: 42
Study 33773391 — intervention group
Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 42
Study 33791916 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone therapy
Number of subjects: 0
Study 33791916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33646835 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxford/AstraZeneca vaccine (ChAdOx1 nCoV‐19)
Number of subjects: 0
Study 34618716 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Grief Disorder (PGD)
Number of subjects: 195
Study 34618716 — intervention group
Group type: COMPARATOR
Intervention: No PGD
Number of subjects: 195
Study 33883174 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogenic FMT (healthy obese donor)
Number of subjects: 24
Study 36136951 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifiform Kids (2 chewable tablets twice per day for 21 days)
Number of subjects: 92
Study 36136951 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probiotics)
Number of subjects: 92
Study 34116393 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium treatment for 12 weeks
Number of subjects: 250
Study 34116393 — intervention group
Group type: COMPARATOR
Intervention: Placebo arm
Number of subjects: 250
Study 33009185 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectus sheath block (RSB) with 2 mg/kg of levobupivacaine
Number of subjects: 97
Study 33009185 — intervention group
Group type: COMPARATOR
Intervention: Spinal anaesthesia with 12.5 mg hyperbaric bupivacaine and 0.5 mg diamorphine
Number of subjects: 97
Study 33009185 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 97
Study 32817406 — intervention group
Group type: EXPERIMENTAL
Intervention: Single high neurofilament light chain (NfL) measure at baseline (BL)
Number of subjects: 274
Study 32817406 — intervention group
Group type: EXPERIMENTAL
Intervention: NfLlong measured over 24 months
Number of subjects: 274
Study 32817406 — intervention group
Group type: EXPERIMENTAL
Intervention: NfLlong combined with clinical and MRI measures
Number of subjects: 274
Study 36057030 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebaudioside A (3 g)
Number of subjects: 30
Study 36057030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 33832143 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved simulation tool training
Number of subjects: 120
Study 33832143 — intervention group
Group type: COMPARATOR
Intervention: Traditional method training
Number of subjects: 120
Study 34339618 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) infusion
Number of subjects: 30
Study 34339618 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (CLON) infusion
Number of subjects: 30
Study 32632246 — intervention group
Group type: EXPERIMENTAL
Intervention: Slaughter equation for body fatness assessment
Number of subjects: 69746
Study 36171022 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening Care for Children (SC4C) intervention
Number of subjects: 21
Study 32461053 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ivermectin (0.1%)‐metronidazole (1%) gel treatment
Number of subjects: 60
Study 32461053 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 60
Study 32633244 — intervention group
Group type: EXPERIMENTAL
Intervention: Manosar® (2 g of d-mannose + 140 mg of proanthocyanidins)
Number of subjects: 283
Study 32633244 — intervention group
Group type: COMPARATOR
Intervention: Isolated PAC (240 mg of continuous-release proanthocyanidins)
Number of subjects: 283
Study 34562471 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered endoscopic debridement (PED) system
Number of subjects: 30
Study 36166391 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact
Number of subjects: 40
Study 36166391 — intervention group
Group type: COMPARATOR
Intervention: Usual procedure
Number of subjects: 40
Study 33592131 — intervention group
Group type: EXPERIMENTAL
Intervention: lipo-PGE1
Number of subjects: 89
Study 33592131 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 89
Study 35042152 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib 600 mg twice daily
Number of subjects: 119
Study 35042152 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (pemetrexed 500 mg/m2 or docetaxel 75 mg/m2, every 3 weeks)
Number of subjects: 119
Study 33217335 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg and 25 mg)
Number of subjects: 7020
Study 33217335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7020
Study 34233727 — intervention group
Group type: COMPARATOR
Intervention: Maintenance therapy with TNFi plus MTX
Number of subjects: 114
Study 34233727 — intervention group
Group type: EXPERIMENTAL
Intervention: Switched therapy with tacrolimus (TAC) plus MTX
Number of subjects: 114
Study 34233727 — intervention group
Group type: EXPERIMENTAL
Intervention: Switched therapy with TAC plus MTX
Number of subjects: 114
Study 34414521 — intervention group
Group type: EXPERIMENTAL
Intervention: MISTms alone
Number of subjects: 36
Study 34414521 — intervention group
Group type: COMPARATOR
Intervention: MISTms combined (with deproteinized bovine bone mineral and collagen membrane)
Number of subjects: 36
Study 34414521 — intervention group
Group type: COMPARATOR
Intervention: MISTms combined
Number of subjects: 36
Study 34009242 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor exercise intervention (n=24), 12-week exercise training program
Number of subjects: 47
Study 34009242 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group (n=23), abstaining from any exercise program
Number of subjects: 47
Study 32586295 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-related walking (low amount)
Number of subjects: 1080
Study 32586295 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-related walking (high amount)
Number of subjects: 1080
Study 32586295 — intervention group
Group type: COMPARATOR
Intervention: Work-related physical activity (any intensity) for professionals
Number of subjects: 1080
Study 32586295 — intervention group
Group type: COMPARATOR
Intervention: Work-related physical activity (any intensity) for sales and service workers
Number of subjects: 1080
Study 34849920 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro maturation (IVM) without stimulation
Number of subjects: 351
Study 34849920 — intervention group
Group type: COMPARATOR
Intervention: Standard in vitro fertilization (IVF) with flexible GnRH antagonist protocol and hCG as ovulatory trigger
Number of subjects: 351
Study 34849920 — intervention group
Group type: COMPARATOR
Intervention: Standard in vitro fertilization (IVF)
Number of subjects: 351
Study 32154591 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomisation (MR)
Number of subjects: 0
Study 34914094 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping Stones and Creating Futures (SSCF) intervention
Number of subjects: 0
Study 35472058 — intervention group
Group type: EXPERIMENTAL
Intervention: Circle of Security-parenting (COS-P)
Number of subjects: 186
Study 35472058 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 186
Study 33788837 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct laryngoscopy (DL)
Number of subjects: 18
Study 33788837 — intervention group
Group type: COMPARATOR
Intervention: Box barrier with direct laryngoscopy (BoxDL)
Number of subjects: 18
Study 36868916 — intervention group
Group type: EXPERIMENTAL
Intervention: AF ablation
Number of subjects: 31
Study 36868916 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 31
Study 33655380 — intervention group
Group type: EXPERIMENTAL
Intervention: IV golimumab 2 mg/kg at Weeks 0, 4, then every 8 weeks through Week 52
Number of subjects: 480
Study 33655380 — intervention group
Group type: COMPARATOR
Intervention: Placebo at Weeks 0, 4, then every 8 weeks, crossover to IV golimumab at Weeks 24, 28, then every 8 weeks through Week 52
Number of subjects: 480
Study 35332807 — intervention group
Group type: EXPERIMENTAL
Intervention: eptinezumab 100 mg
Number of subjects: 1072
Study 35332807 — intervention group
Group type: EXPERIMENTAL
Intervention: eptinezumab 300 mg
Number of subjects: 1072
Study 35332807 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1072
Study 34847938 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on maternal depression (one-day training)
Number of subjects: 12
Study 34847938 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive supervision (for half of the experimental group)
Number of subjects: 12
Study 34847938 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training or supervision)
Number of subjects: 12